Process for preparation of (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt

The present invention relates to processes for the preparation of (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt.

Skip to: Description  ·  Claims  ·  References Cited  · Patent History  ·  Patent History
Description
CROSS REFERENCE TO RELATED APPLICATIONS

This application is a national stage application under 35 U.S.C. §371 of PCT Application No. PCT/IB2006/003153 having an international filing date of Nov. 8, 2006, which designated the United States, which claims the benefit of priority to Indian Patent Application No. 2964/DEL/2005, filed Nov. 8, 2005; Indian Patent Application No. 2967/DEL/2005, filed Nov. 8, 2005, and Indian Patent Application No. 3033/DEL/2005, filed Nov. 14, 2005. The entire disclosure of these patent documents is hereby by reference.

FIELD OF THE INVENTION

The present invention relates to processes for the preparation of (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt.

BACKGROUND OF THE INVENTION

(3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt acts an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, a coenzyme catalyzing the intracellular synthesis of cholesterol, and thus is useful as hypolipidemic and hypocholesterolemic agent, as discussed in PCT Publication No. 04/106299.

Cardiovascular disease and its associated maladies, dysfunctions and complications are a principal cause of disability and the chief cause of death. One specific factor significantly contributing to this pathophysiologic process is atherosclerosis, which has been generally recognized as the leading health care problem both with respect to mortality and health care costs.

Atherosclerosis is characterized by the deposition of fatty substances, primarily cholesterol, resulting in plaque formation on the inner surface of the arterial wall and degenerative change to the arteries. It is now well established that cardiovascular disorders including myocardial infarction, coronary heart disease, hypertension and hypotension, cerebrovascular disorders including stroke, cerebral thrombosis and memory loss due to stroke; peripheral vascular disease and intestinal infarction are caused by blockage of arteries and arterioles by atherosclerotic plaque. Atherosclerotic plaque formation is multi-factorial in its production. Hypercholesterolemia, especially elevated levels of low-density lipoprotein cholesterol (LDL), is an important risk factor for atherosclerosis and arteriosclerosis and associated diseases.

The HMG-CoA reductase inhibitors (statins) have been used in reducing blood levels of LDL cholesterol. Cholesterol is produced via the mevalonic acid pathway. Reducing the formation of mevalonic acid, a precursor to cholesterol, leads to a corresponding decrease in hepatic cholesterol biosynthesis with a reduction in the cellular pool of cholesterol.

A synthetic procedure for preparing (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt has been disclosed in PCT Publication No. WO 04/106299. The aforementioned procedure involves multiple steps involving selective hydrolysis of two chemically similar functionalities e.g. hydrolysis of methyl ester in the presence of tert. -butyl ester, and reduction with sodium borohydride in the presence of iodine or with borane dimethyl sulphide which are expensive reagents and are air- and moisture-sensitive, hence difficult to handle.

SUMMARY OF THE INVENTION

Accordingly, herein are provided processes for preparing (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt by using synthetic procedure incorporating particular intermediates.

Further, herein are provided processes which are simple and economical, avoid the use of expensive and air- and moisture-sensitive reagents, and avoid selective hydrolysis of methyl ester in the presence of tert-butyl ester.

Further, herein are provided processes for the preparation of a compound of Formula I

which processes comprise:

(a) reacting an amine of Formula II with methyl isobutyryl acetate of Formula III

to form a compound of Formula of IV (wherein R is a hydroxy protecting group, for example, acetyl, benzoyl, tetrahydropyranyl, methoxy methyl, methoxy ethoxymethyl, benzyl);

b) reacting the compound of Formula IV with benzaldehyde to form a compound of Formula V;

c) reacting the compound of Formula V with 4-fluorobenzaldehyde to form a compound of Formula VI;

d) reacting the compound of Formula VI with a compound of Formula VII

to form a compound of Formula VIII;

e) subjecting the compound of Formula VIII simultaneously to acid-catalyzed cleavage of ketal and hydroxy protecting group (when R is tetrahydropyranyl) to form a compound of Formula IX;

f) subjecting the compound of Formula IX to base-catalyzed hydrolysis to form a compound of Formula X; and

g) reacting the compound of Formula X with an aqueous solution of calcium acetate to form a compound of Formula I.

This process may involve one or more of the following features. For example, reaction of an amine of Formula II can be carried out in the presence of one or more organic bases such as, for example, triethylamine, pyridine, 1,2-ethylenediamine or mixtures thereof, in one or more aromatic solvents, for example, xylene, toluene or mixtures thereof. In another feature, the reaction of a compound of Formula IV can be carried out in the presence of one or more organic bases such as, for example, piperidine, pyridine, β-alanine or mixtures thereof, one or more organic acids such as, for example, glacial acetic acid or benzoic acid or mixture of organic bases and organic acids, in one or more solvents such as, for example, hydrocarbon solvents (e.g., hexane or heptane), halogenated solvents (e.g., dichloromethane, dichloroethane or chloroform), aromatic solvents (e.g., toluene or xylene) or mixtures thereof. In another feature, the reaction of a compound of Formula V can be carried out in the presence of one or more catalysts such as, for example, sodium cyanide, 3-ethyl-5-(2-hydroxyethyl)-4-methyl thiazolium bromide, 3-benzyl-5-(2-hydroxyethyl)-4-methyl thiazolium chloride or mixtures thereof, one or more organic bases such as, for example, triethylamine, pyridine or mixtures thereof, in a solvent-free condition or in one or more solvents such as, for example, protic polar solvents (e.g., methanol, ethanol, propanol, isopropanol or water), ethers (e.g., dioxan or tetrahydrofuran) or mixtures thereof. In another feature, the reaction of a compound of Formula VI can be carried out in the presence of one or more organic acids such as, for example, pivalic acid, p-toluene sulfonic acid or mixtures thereof, in one or more solvents such as, for example, aromatic solvents (e.g., xylene or toluene), hydrocarbon solvents (e.g., hexane or heptane), ethers (e.g., tetrahydrofuran, dioxane or diethyl ether) or mixtures thereof. In another feature, the cleavage of ketal and hydroxy protecting group of a compound of Formula VIII can be carried out in the presence of one or more mineral acids such as, for example, hydrochloric acid, hydrobromic acid, hydroiodic acid or mixtures thereof, in one or more solvents such as, for example, protic polar solvents (e.g., methanol, ethanol, propanol or water), ethers (e.g., tetrahydrofuran or diethyl ether) or mixtures thereof. In yet another feature, the hydrolysis of a compound of Formula IX can be carried out in the presence of one or more bases such as, for example, lithium hydroxide, sodium hydroxide, potassium hydroxide or mixtures thereof, in one or more solvents such as, for example, protic polar solvents (e.g., methanol, ethanol, propanol, isopropanol or water), ethers (e.g., tetrahydrofuran or diethyl ether) or mixtures thereof.

DETAILED DESCRIPTION OF THE INVENTION

(3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt described herein may be prepared by following, for example, reaction sequences as depicted in Scheme I.

(3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt of Formula I can be prepared, for example, according to Scheme I. Thus, an amine of Formula I can be reacted with methyl isobutyryl acetate of Formula III to form a compound of Formula of IV (wherein R is the same as defined earlier). The compound of Formula IV can be reacted with benzaldehyde to form a compound of Formula V. The compound of Formula V can be reacted with 4-fluorobenzaldehyde to form a compound of Formula VI. The compound of Formula VI can be reacted with a compound of Formula VII to form a compound of Formula VIII. The compound of Formula VIII can be simultaneously subject to acid catalyzed cleavage of ketal and hydroxy protecting group (when R is tetrahydropyranyl) to form a compound of Formula IX. The compound of Formula IX can be subject to alkali base catalyzed hydrolysis to form a compound of Formula X. The compound of Formula X can be further converted to hemi calcium salt of Formula I by following procedures known to those of skill in the art.

The reaction of an amine of Formula II can be carried out in one or more aromatic solvents, for example, xylene, toluene or mixtures thereof. The reaction can also be carried out in the presence of one or more organic bases, for example, triethylamine, pyridine, 1,2-ethylenediamine or mixtures thereof.

The reaction of a compound of Formula IV can be carried out in one or more solvents, for example, hydrocarbon solvents (e.g., hexane or heptane), or halogenated solvents (e.g., dichloromethane, dichloroethane or chloroform), aromatic solvents (e.g., toluene or xylene) or mixtures thereof. The reaction can also be carried out in the presence of one or more organic bases, for example, piperidine, pyridine or β-alanine, one or more organic acids, for example, glacial acetic acid or benzoic acid or mixtures of organic bases and organic acids.

The reaction of a compound of Formula V can be carried out in the presence of one or more catalysts, for example, sodium cyanide, 3-ethyl-5-(2-hydroxyethyl)-4-methyl thiazolium bromide, 3-benzyl-5-(2-hydroxyethyl)-4-methyl thiazolium chloride or mixtures thereof. The reaction can also be carried out in the presence of one or more organic bases, for example, triethylamine, pyridine or mixture thereof, in a solvent-free condition or in one or more solvents, for example, protic polar solvents (e.g., methanol, ethanol, propanol, isopropanol or water), ethers (e.g., dioxan or tetrahydrofuran) or mixtures thereof.

The reaction of a compound of Formula VI can be carried out in one or more solvents, for example, aromatic solvents (e.g., xylene or toluene), hydrocarbon solvents (e.g., hexane or heptane), ethers (e.g., tetrahydrofuran, dioxane or diethyl ether) or mixtures thereof. The reaction can also be carried out in the presence of one or more organic acids, for example, pivalic acid, p-toluene sulfonic acid or mixtures thereof.

The cleavage of ketal and hydroxy protecting group of a compound of Formula VIII can be carried out in the presence of one or more mineral acids, for example, hydrochloric acid, hydrobromic acid, hydroiodic acid or mixtures thereof. The reaction can also be carried out in one or more solvents, for example, protic polar solvents (e.g., methanol, ethanol, propanol or water), ethers (e.g., tetrahydrofuran or diethyl ether) or mixtures thereof. The cleavage of ketal and hydroxy protecting group can also be carried out by any other cleavage method known to those of skill in the art.

The hydrolysis of a compound of Formula IX can be carried out in the presence of one or more bases, for example, lithium hydroxide, sodium hydroxide, potassium hydroxide or mixtures thereof. The reaction can also be carried out in one or more solvents, for example, protic polar solvents (e.g., methanol, ethanol, propanol, isopropanol or water), ethers (e.g., tetrahydrofuran or diethyl ether) or mixtures thereof.

The compound of Formula X can be converted into its corresponding hemi calcium salt of Formula I by following procedure known to those of skill in the art.

In the above schemes, where specific reducing agents, solvents, bases, catalysts, acids etc., are mentioned, it is to be understood that other reducing agents, solvents, bases, catalysts, acids etc., known to those skilled in the art may be used. Similarly, the reaction temperature and duration may be adjusted.

While the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are within the scope of the present invention.

EXAMPLES Example 1 Preparation of 4-methyl-3-oxo-pentanoic acid [4-(tetrahydropyran-2-yloxymethyl)phenyl]amide

A mixture of 4-(tetrahydropyran-2-yloxymethyl)phenyl amine (70 g, 0.34 mol, 1 equiv.) (prepared following the procedure mentioned in J. Med. Chem., 41, 26, (1998), 5297-5309; and Tetrahedron Lett., 43, 30, (2002), 5353), methyl isobutyryl acetate (49 g, 0.34 mol, 1 equiv.), toluene (600 mL) and 1,2-ethylenediamine (2.0 g, 0.034 mol, 0.1 equiv.) was placed in a 2-necked round bottom flask and the reaction mixture was refluxed under a Dean-Stark set up. After completion of the reaction, the solvent was removed under vacuum. The crude product was taken as such for next step. Yield: 116 g (crude)

MS (+ion mode): m/z 320.16 (M+1); 1H NMR (CDCl3, 300 Hz): δ 1.27 (d, J=6 Hz, 6H); 1.33 (s, 2H); 1.54-1.72 (m, 7H); 2.74 (sep, J=6 Hz, 1H); 3.52-3.56 (m, 1H); 3.61 (s, 2H); 3.87-3.95 (m, 1H); 4.47 (d, J=12 Hz, 1H); 4.68 (m, 1H); 4.74 (d, J=12 Hz, 1H); 7.32 (d, J=9 Hz, 2H); 7.53 (d, J=6 Hz, 2H); 9.22 (brs, 1H).

Example 2 Preparation of 2-benzylidine-4-methyl-3-oxo-pentanoic acid [4-(tetrahydro-pyran-2-yloxy methyl)phenyl]amide

A mixture of crude 4-methyl-3-oxo-pentanoic acid [4-(tetrahydropyran-2-yloxy methyl)phenyl]amide (100 g, 0.31 mol, 1 equiv.), β-alanine (5.6 g, 0.063 mol, 0.2 equiv.), benzaldehyde (30.5 mL, 0.31 mol, 1 equiv.), glacial acetic acid (10.6 mL, 0.19 mol, 0.6 equiv.) and hexane (500 mL) was placed in a 2 necked-flask equipped with a Dean-Stark setup. The reaction mixture was refluxed with azeotropic removal of water. At the end of the reaction (TLC monitoring) the solvent was evaporated under reduced pressure to give solid, which was washed with hot hexane, and the solid was collected on a Buchner funnel. The crude compound was purified on column (silica gel, 100-200 mesh, 15% ethyl acetate/hexane) to afford the pure product. Yield: 66.81 g (52.36%).

MS (+ion mode): m/z 408.12 (M+1); 1H NMR (CDCl3, 300 Hz): δ 1.22 (d, J=6.0 Hz, 6H); 1.52-1.85 (m, 8H); 3.35 (sep, J=6 Hz, 1H); 3.52-3.56 (m, 1H); 3.87-3.91 (m, 1H); 4.47 (d, J=12 Hz, 1H); 4.68-4.7 (m, 1H); 4.75 (d, J=12 Hz, 1H); 7.32-7.64 (m, 11H).

Example 3 Preparation of 2-[2-(4-fluorophenyl)-2-oxo-1-phenylethyl]-4-methyl-3-oxo-pentanoic acid [4-(tetrahydropyran-2-yloxy methyl phenyl]amide

A mixture of 2-benzylidine-4-methyl-3-oxo-pentanoic acid [4-(tetrahydropyran-2-yloxy methyl)phenyl]amide (5.0 g, 0.012 mol, 1 equiv.), 4-fluorobenzaldehyde (1.5 mL, 0.0013 mol, 1.1 equiv.), 3-ethyl-5-(2-hydroxyethyl)-4-methyl thiazolium bromide (0.77 g, 0.0003 mol, 0.25 equiv.), triethyl amine (dry, 10 mL, 0.0072 mol, 5.8 equiv.) were placed in round bottom flask, and purged with nitrogen gas. The reaction mixture was refluxed at 90° C. for about 6 hours. After the reaction was over, the reaction mixture was extracted with ethyl acetate and washed with water, and dried over anhydrous sodium sulphate. Organic layer was concentrated and the crude mixture was purified on column (silica gel, 100-200 mesh, 17% ethyl acetate/hexane) to afford the pure product. Yield: 2.52 g (38.6%)

MS (+ion mode): m/z 532.17 (M+1); 1H NMR (CDCl3, 300 Hz): δ 1.15 (d, J=6.0 Hz, 3H); 1.23 (d, J=6.0 Hz, 3H); 1.45-1.851 (m, 6H); 2.85-3.05 (m, 1H); 3.20-3.55 (m, 1H); 3.70-3.95 (m, 1H); 4.40-4.53 (m, 2H); 4.67-4.72 (m, 2H); 5.34 (d, J=9.0 Hz, 1H); 7.01-7.28 (m, 12H); 7.95-8.00 (m, 2H).

Example 4 Preparation of [(4R,6R)-6-(2-{2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-(tetrahydropyran-2-yloxy methyl)phenyl amino)carbonyl]pyrrol-1-yl}ethyl)-2,2-dimethyl-[1,3]dioxan-4-yl]-acetic acid tert-butyl ester

A mixture of 2-[2-(4-fluorophenyl)-2-oxo-1-phenylethyl]-4-methyl-3-oxo-pentanoic acid [4-(tetrahydropyran-2-yloxy methyl)phenyl]amide (2.0 g, 0.004 mol, 1 equiv.), an amine of Formula IX (1.5 g, 0.006 mol, 1.5 equiv.), pivalic acid (0.45 mL, 0.004 mol, 1.03 equiv.), and heptane:toluene:tetrahydrofuran (4:1:1, 24 ml) was placed in a round bottom flask equipped with a Dean-Stark setup. The reaction mixture was refluxed at with azeotropic removal of water. After the completion of reaction (TLC monitoring), the solvents were removed on a rotary evaporator. The residue was diluted with ethyl acetate and a saturated solution of sodium bicarbonate was added to this solution. The aqueous layer was extracted with ethyl acetate and the organic layer was washed with water, brine, dried over anhydrous sodium sulphate and concentrated. The crude mixture was purified on column (silica gel, 100-200 mesh, 15% ethyl acetate/hexane) to obtain the pure product. Yield: 1.0 g (34.6%).

MS (+ion mode): m/z 769.45 (M+1); 1H NMR (CDCl3, 300 Hz): δ 0.9-1.1 (m, 2H); 1.30 (s, 1H), 1.36 (s, 3H); 1.43 (s, 9H); 1.50-1.77 (m, 14 6H); 2.20-2.40 (m, 2H); 3.52-3.70 (m, 3H); 3.85-3.89 (m, 2H); 4.05-4.25 (m, 2H); 4.40 (d, J=12 Hz, 1H); 4.64-4.70 (m, 2H); 6.86-7.25 (m, 14H).

Example 5 Preparation of (3R,5R)-7-[2-(4-fluorophenyl)-4-(4-hydroxymethyl-phenylamino) carbonyl)-5-isopropyl-3-phenylpyrrol-1-yl]-3,5-dihydroxy heptanoic acid tert-butyl ester

A mixture of [(4R,6R)-6-(2-{2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-(tetrahydro-pyran-2-yloxy methyl)phenyl amino)carbonyl]-pyrrol-1-yl}ethyl)-2,2-dimethyl-[1,3]dioxan-4-yl]-acetic acid tert-butyl ester (0.8 g, 0.0015 mol, 1 equiv.) and a mixture of 1 N hydrochloric acid:methanol:tetrahydrofuran in the ratio 2:5:5 (24 mL) was placed in a single neck flask. The reaction mixture was stirred at room temperature. Reaction mixture was concentrated by evaporating solvent under reduced pressure. The crude compound was extracted with ethyl acetate and the ethyl acetate layer was washed with brine, dried over anhydrous sodium sulphate and concentrated. The crude mixture was purified on column (silica gel, 100-200 mesh, 60% ethyl acetate/hexane) to obtain the pure product. Yield: 446 mg (66.56%).

MS (+ion mode): m/z 645.32 (M+1); 1H NMR (CDCl3, 300 Hz): δ 1.15-1.30 (m, 2H); 1.45 (s, 9H); 1.47-1.62 (m, 8H); 2.32 (d, J=6.0 Hz, 2H); 3.53-3.60 (m, 2H); 3.69-3.92 (m, 1H); 4.08-4.13 (m, 2H); 4.58 (s, 2H); 6.87 (s, 1H); 6.97-7.25 (m, 13H).

Example 6 Preparation of (3R,5R)-7-[2-(4-fluorophenyl)-4-(4-hydroxy methyl-phenyl amino) carbonyl)-5-isopropyl-3-phenyl-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt

Step 1: (3R,5R)-7-[2-(4-fluorophenyl)-4-(4-hydroxy methyl phenyl amino) carbonyl)-5-isopropyl-3-phenylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid tert-butyl ester in a mixture of methanol-tetrahydrofuran (1:1) was cooled to 0° C. and sodium hydroxide pellets were added. The reaction mixture was then stirred at an ambient temperature. At the end of ester hydrolysis, solvents were removed and the residue was dissolved in water, and the aqueous layer was washed with ether.

Step 2: To an aqueous solution of sodium salt of (3R,5R)-7-[2-(4-fluorophenyl)-4-(4-hydroxy methyl-phenyl amino)carbonyl)-5-isopropyl-3-phenyl-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid was added drop wise an aqueous solution (1M) of calcium acetate (0.55 equiv.). White precipitate was obtained, which was filtered off, washed with copious amount of water, and dried in vacuo. Yield=63.4%

MS (positive ion mode): m/z 589 (Acid+1); m.p.=189-204° C.; 1H NMR (DMSO-d6): δ 1.22-1.62 (m, 11H), 1.98 (dd, J=15 & 8.1 Hz, 1H), 2.06-2.16 (m, 1H), 3.25-3.37 (m, 2H), 3.57 (brs, 2H), 3.80 (brs, 1H), 4.43 (s, 2H), 7.03-7.28 (m, 12H), 7.50 (d, J=6H, 2H), 9.80 (s, 1H)

Claims

1. A method for the preparation of (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt of Formula I, comprising: to form a compound of Formula of IV, wherein R is a hydroxy protecting group selected from the group consisting of acetyl, benzoyl, tetrahydropyranyl, methoxy methyl, methoxy ethoxymethyl, and benzyl;

(a) reacting an amine of Formula II with methyl isobutyryl acetate of Formula III
b) reacting the compound of Formula IV with benzaldehyde to form a compound of Formula V;
c) reacting the compound of Formula V with 4-fluorobenzaldehyde to form a compound of Formula VI;
d) reacting the compound of Formula VI with a compound of Formula VII
to form a compound of Formula VIII;
e) subjecting the compound of Formula VIII with a mineral acide simultaneously to induce acid-catalyzed cleavage of ketal and the hydroxy protecting groups to form a crude compound of Formula IX;
f) purifying the crude compound of Formula IX to form a purified compound of Formula IX;
g) subjecting the purified compound of Formula IX with a base to induce base-catalyzed hydrolysis to form a compound of Formula X; and
h) reacting the compound of Formula X with aqueous solution of calcium acetate to form a compound of Formula I.

2. The process of claim 1, wherein the reaction of the amine of Formula II is carried out

i) in the presence of one or more organic bases; and
ii) in one or more aromatic solvents.

3. The process of claim 1, wherein the reaction of the compound of Formula IV is carried out

i) in the presence of one or more organic bases selected from the group consisting of piperidine, pyridine, and β-alanine; or in the presence off one or more organic acids selected from the group consisting of glacial acetic acid and benzoic acid; or in the presence of a mixture of organic bases or organic acids; and
ii) in one or more solvents selected from the group consisting of hexane, heptane, dichloromethane, dichloroethane, chloroform, toluene, xylene, and mixtures thereof.

4. The process of claim 1, wherein the reaction of the compound of Formula V is carried out

i) in the presence of one or more catalysts selected from the group consisting of sodium cyanide, 3-ethyl-5-(2-hydroxyethyl)-4-methyl thiazolium bromide, 3-benzyl-5-(2-hydroxyethyl)-4-methyl thiazolium chloride and mixtures thereof;
ii) in the presence of one or more organic bases selected from the group consisting of triethylamine, pyridine and mixtures thereof; and
iii) in a solvent-free condition or in one or more solvents selected from the group consisting of methanol, ethanol, propanol, isopropanol, water, dioxin, tetrahydrofuran, and mixtures thereof.

5. The process of claim 1, wherein the reaction of a compound of Formula VI is carried out

i) in the presence of one or more organic acids selected from the group consisting of pivalic acid, p-toluene sulfonic acid, and mixtures thereof; and
ii) in the presence of one or more solvents selected from the group consisting of xylene, toluene, hexane, and heptanes, tetrahydrofuran, dioxane, diethyl ether, and mixtures thereof.

6. The process of claim 1, wherein the cleavage of ketal and hydroxy protecting groups of the compound of Formula VIII is carried out

i) in the presence of one or more mineral acids selected from the group consisting of hydrochloric acid, hydrobromic acid, hydroiodic acid, and mixtures thereof; and
ii) in the presence of one or more solvents selected from the group consisting of methanol, ethanol, propanol, water, tetrahydrofuran, diethyl ether, and mixtures thereof.

7. The process of claim 1, wherein the hydrolysis of a compound of Formula IX is carried out

i) in the presence of one or more bases selected from the group consisting of lithium hydroxide, sodium hydroxide, potassium hydroxide and mixtures thereof; and
ii) in the presence of one or more solvents selected from the group consisting of methanol, ethanol, propanol, isopropanol, water, tetrahydrofuran, diethyl ether, and mixtures thereof.

8. The process of claim 1, wherein the crude compound of Formula IX is purified by a column.

Referenced Cited
U.S. Patent Documents
3262977 July 1966 Harsanyi et al.
3341584 September 1967 Larsen
3454635 July 1969 Weber
3471515 October 1969 Troxler
3483221 December 1969 Wilhelm
3527761 September 1970 Archibald
3562257 February 1971 Kugita
3576883 April 1971 Neuworth
3642896 February 1972 Collin
3644353 February 1972 Lunts et al.
3649691 March 1972 Shavel
3655663 April 1972 Wasson
3663570 May 1972 Sato
3663706 May 1972 Hess et al.
3669968 June 1972 Hess
3674836 July 1972 Creger
3705233 December 1972 Lunts et al.
3716583 February 1973 Nakamura et al.
3723446 March 1973 Scherm et al.
3773939 November 1973 Janssen
3781328 December 1973 Witte
3850941 November 1974 Irikura
3857891 December 1974 Holmes et al.
3857952 December 1974 Wooldridge et al.
3868460 February 1975 Koppe et al.
3879554 April 1975 Temperilli
3910924 October 1975 Tamura et al.
3912743 October 1975 Christensen et al.
3932400 January 13, 1976 Hibino et al.
3932645 January 13, 1976 Meyer et al.
3934032 January 20, 1976 Barrett et al.
3937838 February 10, 1976 Wetterlin et al.
3948943 April 6, 1976 Eberhardt et al.
3962238 June 8, 1976 Mauvernay et al.
3982021 September 21, 1976 Hauck et al.
3984413 October 5, 1976 Metz et al.
3994974 November 30, 1976 Murakami et al.
3997666 December 14, 1976 Witte et al.
3998790 December 21, 1976 Brandstrom et al.
4011258 March 8, 1977 Wetterlin et al.
4012444 March 15, 1977 Lunts et al.
4032648 June 28, 1977 Malen et al.
4034009 July 5, 1977 Zolss et al.
4051143 September 27, 1977 Scherm et al.
4056626 November 1, 1977 Ito et al.
4058552 November 15, 1977 Mieville
4062950 December 13, 1977 Frommer et al.
4105776 August 8, 1978 Ondetti et al.
4129565 December 12, 1978 Fukushima et al.
4154839 May 15, 1979 Wehinger et al.
4182767 January 8, 1980 Murai et al.
4188390 February 12, 1980 Campbell
4217305 August 12, 1980 Imai et al.
4248883 February 3, 1981 Sawayama et al.
4252721 February 24, 1981 Silvestrini et al.
4252825 February 24, 1981 Demarne
4252984 February 24, 1981 Manoury et al.
4258062 March 24, 1981 Jonas et al.
4260622 April 7, 1981 Junge et al.
4264611 April 28, 1981 Berntsson et al.
4310549 January 12, 1982 Hajos et al.
4314081 February 2, 1982 Molloy et al.
4337201 June 29, 1982 Petrillo, Jr.
4344949 August 17, 1982 Hoefle et al.
4410520 October 18, 1983 Watthey
4425355 January 10, 1984 Hoefle et al.
4434176 February 28, 1984 Troxler et al.
4444779 April 24, 1984 Kawamatsu et al.
4448964 May 15, 1984 Muto et al.
4466972 August 21, 1984 Neumann
4470972 September 11, 1984 Gold et al.
4472380 September 18, 1984 Harris et al.
4503067 March 5, 1985 Wiedemann et al.
4508729 April 2, 1985 Vincent et al.
4522828 June 11, 1985 Jeffery et al.
4572909 February 25, 1986 Campbell et al.
4587258 May 6, 1986 Gold et al.
4598089 July 1, 1986 Hadvary et al.
4663325 May 5, 1987 Ohtaka et al.
4672068 June 9, 1987 Kutsuma et al.
4681893 July 21, 1987 Roth
4687777 August 18, 1987 Meguro et al.
4699905 October 13, 1987 Yanagisawa et al.
4701559 October 20, 1987 Horii et al.
4705797 November 10, 1987 Nardi et al.
4731478 March 15, 1988 Niigata et al.
4734280 March 29, 1988 Braquet
4801599 January 31, 1989 Semeraro et al.
4822818 April 18, 1989 Oka et al.
4873259 October 10, 1989 Summers, Jr. et al.
4879303 November 7, 1989 Davison et al.
4994461 February 19, 1991 Ulrich
5002953 March 26, 1991 Hindley
5049559 September 17, 1991 Braquet et al.
5128355 July 7, 1992 Carini et al.
5155103 October 13, 1992 Weber et al.
5155120 October 13, 1992 Lazar et al.
5185351 February 9, 1993 Finkelstein et al.
5273995 December 28, 1993 Roth
5274094 December 28, 1993 Whittaker et al.
5344914 September 6, 1994 Gibson et al.
5349056 September 20, 1994 Panayotatos
5356896 October 18, 1994 Kabadi et al.
5385929 January 31, 1995 Bjorge et al.
5399578 March 21, 1995 Buhlmayer et al.
5422351 June 6, 1995 Piwinski et al.
5424286 June 13, 1995 Eng
5466823 November 14, 1995 Talley et al.
5474995 December 12, 1995 Ducharme et al.
5491172 February 13, 1996 Lee et al.
5492906 February 20, 1996 Braquet et al.
5510332 April 23, 1996 Kogan et al.
5541183 July 30, 1996 Park et al.
5552438 September 3, 1996 Christensen, IV
5559233 September 24, 1996 Bernhart et al.
5624941 April 29, 1997 Barth et al.
5633272 May 27, 1997 Talley et al.
5693675 December 2, 1997 Mandeville, III et al.
5712298 January 27, 1998 Amschler
5733931 March 31, 1998 Yamada et al.
5744501 April 28, 1998 Norden
5753653 May 19, 1998 Bender et al.
5767115 June 16, 1998 Rosenblum et al.
5932598 August 3, 1999 Talley et al.
5968982 October 19, 1999 Voss et al.
5985322 November 16, 1999 Anderson et al.
5990173 November 23, 1999 Patoiseau et al.
5994510 November 30, 1999 Adair et al.
6015557 January 18, 2000 Tobinick et al.
6147090 November 14, 2000 DeNinno et al.
6197786 March 6, 2001 DeNinno et al.
6268392 July 31, 2001 Keller et al.
6329336 December 11, 2001 Bridon et al.
6329344 December 11, 2001 Arora et al.
6395751 May 28, 2002 DeNinno et al.
6420417 July 16, 2002 Keller et al.
6426365 July 30, 2002 Shinkai et al.
6489478 December 3, 2002 DeNinno et al.
6511985 January 28, 2003 Ippen et al.
6534088 March 18, 2003 Guivarc'h et al.
6569461 May 27, 2003 Tilyer et al.
6586448 July 1, 2003 DeNinno et al.
6590085 July 8, 2003 Arora et al.
6642268 November 4, 2003 Keller et al.
6753346 June 22, 2004 Shinkai et al.
6787570 September 7, 2004 Sikorski et al.
6794396 September 21, 2004 Lee et al.
6803388 October 12, 2004 Sikorski et al.
6884226 April 26, 2005 Pereira
7056936 June 6, 2006 Kilian et al.
7361772 April 22, 2008 Mathew et al.
20020052312 May 2, 2002 Reiss et al.
20030153617 August 14, 2003 Dalen et al.
20040029962 February 12, 2004 Chen et al.
20040053842 March 18, 2004 Nguyen et al.
20040097555 May 20, 2004 Ohkawa et al.
20040132771 July 8, 2004 Babcock et al.
20050032878 February 10, 2005 Deboeck et al.
20050063911 March 24, 2005 Nilsson et al.
20050187204 August 25, 2005 Kondo et al.
20070238716 October 11, 2007 Murthy et al.
20070259874 November 8, 2007 Palle et al.
20080153896 June 26, 2008 Yadav et al.
20080248035 October 9, 2008 Sattigeri et al.
20080287690 November 20, 2008 Kaul et al.
Foreign Patent Documents
0247633 December 1987 EP
0409281 January 1991 EP
0419049 March 1991 EP
0542355 May 1993 EP
0542356 May 1993 EP
0606646 July 1994 EP
0651739 May 1995 EP
0680963 November 1995 EP
0753298 January 1997 EP
0818197 January 1998 EP
0818448 January 1998 EP
0842943 May 1998 EP
0903353 March 1999 EP
0905139 March 1999 EP
0918059 May 1999 EP
1488808 December 2004 EP
1510208 March 2005 EP
1523316 April 2005 EP
2279430 July 2006 RU
72290 September 2002 UA
WO 95/15973 June 1995 WO
WO 95/28926 November 1995 WO
WO 96/01644 January 1996 WO
WO 96/06108 February 1996 WO
WO 96/20216 July 1996 WO
WO 96/22966 August 1996 WO
WO 96/31206 October 1996 WO
WO 96/40641 December 1996 WO
WO 96/40781 December 1996 WO
WO 97/02289 January 1997 WO
WO 97/03094 January 1997 WO
WO 97/16184 May 1997 WO
WO 97/22619 June 1997 WO
WO 98/19998 May 1998 WO
WO 98/27098 June 1998 WO
WO 98/47892 October 1998 WO
WO 98/53814 December 1998 WO
WO 98/53817 December 1998 WO
WO 98/53818 December 1998 WO
WO 98/54207 December 1998 WO
WO 99/20110 April 1999 WO
WO 99/23063 May 1999 WO
WO 99/24398 May 1999 WO
WO 99/35163 July 1999 WO
WO 99/36393 July 1999 WO
WO 99/37605 July 1999 WO
WO 99/37618 July 1999 WO
WO 99/43642 September 1999 WO
WO 99/47138 September 1999 WO
WO 99/47547 September 1999 WO
WO 99/54321 October 1999 WO
WO 99/58505 November 1999 WO
WO 99/58902 November 1999 WO
WO 99/61465 December 1999 WO
WO 99/67230 December 1999 WO
WO 00/00477 January 2000 WO
WO 00/01690 January 2000 WO
WO 00/05223 February 2000 WO
WO 00/05224 February 2000 WO
WO 00/15612 March 2000 WO
WO 00/18759 April 2000 WO
WO 00/18760 April 2000 WO
WO 00/35425 June 2000 WO
WO 00/43384 July 2000 WO
WO 01/13953 March 2001 WO
WO 01/32127 May 2001 WO
WO 01/37831 May 2001 WO
WO 01/42246 June 2001 WO
WO 01/93860 December 2001 WO
WO 02/096422 December 2002 WO
WO 03/007993 January 2003 WO
WO 03/013607 February 2003 WO
WO 03/013608 February 2003 WO
WO 03/066063 August 2003 WO
WO 03/077896 September 2003 WO
WO 03/080070 October 2003 WO
WO 03/088962 October 2003 WO
WO 03/094923 November 2003 WO
WO 2004/004777 January 2004 WO
WO 2004/004778 January 2004 WO
WO 2004/014896 February 2004 WO
WO 2004/019985 March 2004 WO
WO 2004/028456 April 2004 WO
WO 2004/039373 May 2004 WO
WO 2004/056359 July 2004 WO
WO 2004/056395 July 2004 WO
WO 2004/062557 July 2004 WO
WO 2004/067006 August 2004 WO
WO 2004/098583 November 2004 WO
WO 2004/106299 December 2004 WO
WO 2005/009340 February 2005 WO
WO 2005/014539 February 2005 WO
WO 2005/018626 March 2005 WO
WO 2005/021515 March 2005 WO
WO 2005/026163 March 2005 WO
WO 2005/034908 April 2005 WO
WO 2005/041864 May 2005 WO
WO 2005/051931 June 2005 WO
WO 2005/056536 June 2005 WO
WO 2005/058813 June 2005 WO
WO 2005/058898 June 2005 WO
WO 2005/100318 October 2005 WO
WO 2005/100331 October 2005 WO
WO 2006/085212 August 2006 WO
WO 2006/117743 November 2006 WO
WO 2007/054789 May 2007 WO
WO 2007/054790 May 2007 WO
WO 2007/054896 May 2007 WO
Other references
  • International Search Report prepared by the European Patent Office on Feb. 15, 2007 for PCT/IB2006/003153; Applicant, Ranbaxy Laboratories Limited.
  • “Prevent” definition from dictionary.com, accessed Nov. 28, 2007.
  • Bedford et al., “Nonquaternary Cholinesterase Reactivators. 3. 3(5)- Substituted 1,2,4-Oxadiazol-5(3)-aldoximes and 1,2,4-Oxidiazole-5(3)-thiocarbohydroximates as Reactivators of Organophosphonate-Inhibited Eel and Human Acetylcholinesterase in Vitro”, Journal of Medicinal Chemistry, 29(11):2174-2183 (1986).
  • Carr et al., “Enzymatic Determination of Triglyceride, Free Cholesterol, and Total Cholesterol in Tissue Lipid Extracts”, Clin. Biochem., 26:39-42 (1993).
  • Ruys et al., “The Estimation of Serum Triglycerides by Nephelometry: A Simple Method for the Estimation of Serum Triglycerides Suitabe for the Small Laboratory”, Med. J. Aust., 22(1):385-387 (1975).
  • Niculescu-Duvaz D et al., “Self-Immolative Nitrogen Mustard Profdrugs for Suicide Gene Therapy”, J. Med. Chem. 41(26):5297-5309 (1998).
  • Nakanishi, K., “Terpene trilactones from Gingko bioloba: From ancient times to the 21st century”, Bioorg. Med. Chem., 13:4987-5000 (2005).
  • Rinaldi-Carmona et al., “Biochemical and Pharmacological Characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist”, Life Sci., 56:1941-1947 (1995).
  • Rodriguez-Sureda et al., “A Procedure for measuring triacylglyceride and cholesterol content using a small amount of tissue”, Anal. Biochem., 343:277-282 (2005).
  • Karimi et al., “Lithium triflate (LiOTf) catalyzed efficient and chemoselective tetrahydropyranylation of alcohols and phenols under mild and neutral reaction conditions”, Tetrahedron Lett., 43(30):5353 (2002).
  • Wilson et al., “Estimation of VLDL cholesterol in hyperlipidemia”, Clin. Chim. Acta., Oct. 15; 1513:285-291 (1985).
  • Zhang et al., “Niacin mediates lipolysis in adipose tissue through its G-protein coupled receptor HM74A”, Biochem and Biophys. Res. Commun., 334:729-732 (2005).
  • Examination Report for European Patent Application No. 06820873.5, dated Mar. 25, 2009.
  • International Preliminary Report on Patentability for International (PCT) Patent Application No. PCT/IB2006/003153, mailed May 22, 2008.
  • U.S. Appl. No. 10/558,859, filed Nov. 30, 2005, Salman et al.
  • Allain et al., Clin. Chem., 20:470 (1974).
  • Antibacterial & Antifungal Drug Discovery & Development Summit, Strategic Research Institute, Jun. 28-29, 2001, Amsterdam, The Netherlands.
  • Baumann et al., “The Convergent Synthesis of CI-981, an Optically Active, Highly Potent, Tissue Selective Inhibitor of HMG-COA Reductase”, Tetrahedron Letters, Elsevier, vol. 33, No. 17, Apr. 21, 1992, pp. 2283-2284.
  • Bedford et al., “Nonquaternary Cholinesterase Reactivators. 3. 3(5)- Substituted 1,2,4-Oxadiazol-5(3)-aldoximes and 1,2,4-Oxidiazole-5(3)-thiocarbohydroximates as Reactivators of Organophosphonate-Inhibited Eel and Human Acetylcholinesterase in Vitro”, Journal of Medicinal Chemistry, 29(11):2174-2183 (1986).
  • Cui et al., J. Biol. Chem., 278:10214-10220 (2003).
  • Dolinsky et al., Biochem. J., 378:967-974 (2004).
  • Frederikson et al., J. Lipid Res., 45:592-601 (2004).
  • Friedewald et al., Clin. Chem., 18:6, pp. 499-502 (1972).
  • Frings et al., Clin. Chem., 18(7), pp. 673-674 (1972).
  • Fujino et al., “Metabolic properties of the acid and lactone froms of HMG-CoA reductasse inhibitors”, Xenobiotica, Nov./Dec. 2004, vol. 34, No. 11/12, pp. 961-971.
  • Harwood et al., J. Lipid Res., 34:377-395 (1993).
  • Heller et al., “Solubilization and Partial Purification of Hepatic 3-Hydroxy-3Methylglutaryl Coenzyme a Reductase,” Biochemical and Biophysical Research Communications, 50(3): 859-865 (1973).
  • Kubo and Strott, “Differential Activity of 3-Hydroxy-3-Methylglutaryl Coenzyme a Reductase in Zones of the Adrenal Cortex,” Endocrinology, 120(1):214-221 (1987).
  • Lorenzen et al., Mol. Pharmacol., 59:349-357 (2001).
  • Meyer et al., “Annulation of a,b-Unsaturated Ketones by a Micael Addition-Cyclization Sequence. A Versatile Syntesis of Alicyclic Six-Membered Rings”, Journal of Organice Chemistry, 50(4):438-447 (1985).
  • Renodon-Corniere et al., “N-Aryl N'Hydroxyguanidines, A New Class of NO-Donors after Selective Oxidation by Nitric Oxide Synthases: Structure-Activity Relationship,” Journal of Medicinal Chemistry, 45(4):944-954 (2002).
  • Rifai et al., Clin. Chem., 32(6):957-961 (1986).
  • Sampson et al., Clin. Chem., 47(3):532-539 (2001).
  • Shefer et al., J. Lipid Res., 22:532-536 (1981).
  • Sun et al., “A general Sythesis of dioxolenone prodrug moieties”, Tetrahedron Letters, 43:1161-1164 (2002).
  • U.S. Appl. No. 60/498,947, filed Aug. 29, 2003, entitled “Isoxazoline derivatives as inhibitors or phophodiesterase type-IV”.
  • Written Opinion for International (PCT) Patent Application No. PCT/IB2006/003153, mailed Feb. 27, 2007.
  • International Preiliminary Report on Patentability for International (PCT) Patent Application No. PCT/IB2006/003153, mailed May 22, 2008.
Patent History
Patent number: 7671216
Type: Grant
Filed: Nov 8, 2006
Date of Patent: Mar 2, 2010
Patent Publication Number: 20090118520
Assignee: Ranbaxy Laboratories Limited (New Delhi)
Inventors: Jitendra Anant Sattigeri (Gurgaon), Sachin Sethi (Yamuna Nagar), Kaushal Kishore (Nalanda)
Primary Examiner: Kamal A Saeed
Assistant Examiner: Samantha L Shterengarts
Attorney: Sheridan Ross P.C.
Application Number: 12/092,813
Classifications
Current U.S. Class: Nitrogen Attached Indirectly To The Five-membered Hetero Ring By Acyclic Nonionic Bonding (548/561)
International Classification: C07D 207/30 (20060101);